Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the m…
Sign in to search companies, open filing PDFs, fetch uncached SEDAR+ documents, and use the
full company research view.
Results 2026-03-16
Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026
News release - English.pdf
Results 2026-03-16 Financials
Interim MD&A - English.pdf
Results 2026-03-16 Financials
Interim financial statements/report – English.pdf
News 2026-02-24
Helix Biopharma Corp. Announces Presentation at 16th Annual World ADC London
News release - English.pdf
News 2026-02-05
Helix Biopharma Corp. Extends LEUMUNA™ Option with metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases
News release - English.pdf
News 2025-12-31
Certificate re dissemination to shareholders.pdf
News 2025-12-31
Other.pdf
Results 2025-12-12 Financials
Interim MD&A - English.pdf
Results 2025-12-12 Financials
Interim financial statements/report – English.pdf
Results 2025-11-12 Financials
Annual MD&A (amended) - English.pdf
Results 2025-11-12 Financials
Revised annual information form - English.pdf
Results 2025-10-29 Financials
Annual information form - English.pdf
News 2025-10-29
News release - English.pdf
Results 2025-10-29 Financials
Annual MD&A - English.pdf
Results 2025-10-29 Financials
Audited annual financial statements – English.pdf
News 2025-10-07
Material change report - English.pdf
News 2025-10-06
News release - English.pdf
News 2025-09-10
News release - English.pdf
News 2025-09-05
News release - English.pdf
News 2025-08-29
Report of exempt distribution (45-106F1).pdf
News 2025-08-22
News release - English.pdf
Ownership 2025-07-29
Mehrling, Thomas Jorg Heinrich bought +$47k
Insider trading – 2025-07-29
1 insider · +$47k net
News 2025-06-19
Material change report - English.pdf
News 2025-06-16
News release - English.pdf
Results 2025-06-16 Financials
Interim MD&A - English.pdf
Results 2025-06-16 Financials
Interim financial statements/report – English.pdf
News 2025-06-03
Material change report - English.pdf
News 2025-06-02
News release - English.pdf
Ownership 2025-05-22
Mehrling, Thomas Jorg Heinrich bought +$20.0M
Insider trading – 2025-05-22
1 insider · +$20.0M net
Ownership 2024-07-26
Wilczewski, Jerzy sold +$3.3M
Insider trading – 2024-07-26
1 insider · −$3.3M net